{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:30:39Z","timestamp":1791898239886,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jare.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T20:18:51Z","timestamp":1537388331000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data"],"prefix":"10.1016","volume":"15","author":[{"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Del Zotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Zanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-0897","authenticated-orcid":false,"given":"Francesca","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jare.2018.09.003_b0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11926-999-0013-5","article-title":"Biologic therapies in rheumatoid arthritis","volume":"1","author":"Bulpitt","year":"1999","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jare.2018.09.003_b0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jare.2018.09.003_b0020","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jare.2018.09.003_b0025","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jare.2018.09.003_b0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.jare.2018.09.003_b0035","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9990","key":"10.1016\/j.jare.2018.09.003_b0045","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jare.2018.09.003_b0050","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jare.2018.09.003_b0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12891-015-0805-x","article-title":"The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment","volume":"16","author":"Macfarlane","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jare.2018.09.003_b0060","first-page":"1","article-title":"Administrative health databases for addressing emerging issues in adults with CHD: a systematic review","volume":"29","author":"Cohen","year":"2018","journal-title":"Cardiol Young"},{"issue":"2","key":"10.1016\/j.jare.2018.09.003_b0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jorc.12192","article-title":"Inception and utility of a renal replacement registry using administrative health data in North-East Italy","volume":"43","author":"Valent","year":"2017","journal-title":"J Ren Care"},{"key":"10.1016\/j.jare.2018.09.003_b0070","unstructured":"Ministero della Salute. Elenco malattie e condizioni croniche e invalidanti. Allegato 8 DPCM 12 gennaio 2017. <http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=18\/03\/2017&redaz=17A02015&artp=13&art=1&subart=1&subart1=10&vers=1&prog=001> [accessed 24 April 2018]."},{"key":"10.1016\/j.jare.2018.09.003_b0075","unstructured":"Ministero della Salute. Elenco malattie rare esentate dalla partecipazione al costo. Allegato 7 DPCM 12 gennaio; 2017. <http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=18\/03\/2017&redaz=17A02015&artp=12&art=1&subart=1&subart1=10&vers=1&prog=001> [accessed 24 April 2018]."},{"key":"10.1016\/j.jare.2018.09.003_b0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jare.2018.09.003_b0085","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis","volume":"5","author":"Singh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0090","first-page":"1","article-title":"One year in review 2017: spondyloarthritis","volume":"36","author":"Terenzi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.jare.2018.09.003_b0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-016-3631-z","article-title":"Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis","volume":"37","author":"Kawashima","year":"2017","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.jare.2018.09.003_b0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40266-015-0341-2","article-title":"Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs","volume":"33","author":"Sugihara","year":"2016","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.jare.2018.09.003_b0105","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Society of Rheumatology. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"10.1016\/j.jare.2018.09.003_b0110","doi-asserted-by":"crossref","first-page":"e9930","DOI":"10.1097\/MD.0000000000009930","article-title":"Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results","volume":"97","author":"Armagan","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.jare.2018.09.003_b0120","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jare.2018.09.003_b0125","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0130","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/rmdopen-2016-000406","article-title":"Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis","volume":"3","author":"Hua","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.39416","article-title":"Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs","volume":"68","author":"Accortt","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jare.2018.09.003_b0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jare.2018.09.003_b0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.13013","article-title":"Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jare.2018.09.003_b0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11926-017-0692-2","article-title":"Cardiometabolic disorders in psoriatic disease","volume":"26;19(10)","author":"Sobchak","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.jare.2018.09.003_b0155","first-page":"1","article-title":"Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature","volume":"22","author":"Abrouk","year":"2017","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jare.2018.09.003_b0160","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.101149","article-title":"The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases","volume":"38","author":"Bernatsky","year":"2011","journal-title":"J Rheumatol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012321830095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012321830095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:44:37Z","timestamp":1761857077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012321830095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"alternative-id":["S209012321830095X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2018.09.003","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Production and hosting by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}